Repurposing cinacalcet suppresses multi-drug resistant Staphylococcus aureus by disruption of cell membrane and inhibits biofilm by targeting IcaR
Ontology highlight
ABSTRACT: Multi-drug resistant Staphylococcus aureus (S. aureus) infections continously threaten public health. The rapid escalation in morbidity and mortality rates associated with methicillin-resistant S. aureus (MRSA) infections necessitates the urgent development of novel antimicrobial agents. Our study reveals that the FDA-approved drug cinacalcet (CNA) effectively functions as an antibacterial and anti-biofilm agent against S. aureus without detectable resistance. It evidently improved survival rate of mice infected with clinical multi-resistant S. aureus in a pneumonia model. Subsequent proteomic and biochemical experiments suggest that the primary antibacterial mechanism involves membrane structure disruption, ATP content reduction, and reactive oxygen species (ROS) production. Concurrently, LiP-SMap combined with biochemical validation indicates that CNA inhibits biofilm formation by targeting IcaR, a negative regulator of icaADBC, thereby enhancing its binding capacity to the ica operator DNA and subsequently suppressing extracellular polysaccharide formation. Importantly, compared to vancomycin, CNA demonstrates stronger biofilm bacterial clearance in a mouse thigh infection model. Collectively, our findings propose that CNA can be repurposed as a potential therapeutic agent for treating multidrug-resistant S. aureus infections and their associated biofilms.
INSTRUMENT(S): Orbitrap Fusion Lumos
ORGANISM(S): Staphylococcus Aureus
SUBMITTER: Zuye Fang
LAB HEAD: Xuesong Sun
PROVIDER: PXD041266 | Pride | 2024-02-07
REPOSITORIES: Pride
ACCESS DATA